The story of the erectile dysfunction drug presents a challenging picture for investors. While the initial release generated substantial returns, the expiration of its intellectual property protection opened the floodgates to off-brand versions, dramatically reducing market share. This poses a particular risk for pharmaceutical companies banking on

The legacy of Viagra, and its creator copyright, presents a complex case study for investors. Initially a blockbuster drug, generating billions in income, its patent expiration created a wave of lower-priced alternatives , significantly diminishing its market share . While specific pharmaceutical companies may attempt to capitalize on similar condi